Table 4.
Adjusted Hazard Ratios for cardiovascular events based on duration of endocrine therapy.
| Endocrine therapy | Type of cardiovascular event, HR (95% CI) |
|||
|---|---|---|---|---|
| Heart failure or cardiomyopathy | Arrythmia | Acute ischemic heart disease | Ischemic stroke or TIA | |
|
Tamoxifen duration, years | ||||
| Non-users or < 1 y | 1 | 1 | 1 | 1 |
| 1–2 y | 1.21 (0.13–19.72) | 1.59 (0.88–2.57) | 0.86 (0.57–1.30) | 0.70 (0.27–1.85) |
| 3–4 y | 0.95 (0.06–15.29) | 1.12 (0.74–1.69) | 0.32 (0.19–0.55) | 1.78 (0.86–3.69) |
| >4 y |
0.67 (0.04–10.70) |
1.05 (0.71–1.55) |
0.45 (0.25–0.51) |
2.00 (1.05–3.84) |
|
Aromatase inhibitors, years | ||||
| Non-users or < 1 y | 1 | 1 | 1 | 1 |
| 1–2 y | 1.96 (0.21–19.11) | 1.57 (0.43–2.18) | 1.47 (0.91–2.40) | 1.83 (0.98–3.40) |
| 3–4 y | 2.19 (0.47–17.55) | 1.47 (0.60–1.83) | 1.18 (0.81–1.70) | 1.12 (0.48–2.58) |
| >4 y | 2.72 (0.66–26.09) | 2.12 (1.40–3.25) | 2.03 (1.15–3.58) | 1.16 (0.55–2.46) |
Abbreviations: HR, Hazard Ratio; CI, Confidence Interval; TIA, Transient Ischemic Attack; y, years. Adjustment includes following covariates: Age, side, stage, chemotherapy, Trastuzumab, surgical procedure, radiation therapy, CCI, marital status and family income.